Solgate’s CEO Ariel Bensimon presented the company technology platform and recent scientific results at the final ReSOLUTE consortium conference held in Vienna. Surrounded by a scenic venue and a thriving and growing community of scientists passionate about transporters, he highlighted the systematic and platform-based approach Solgate is taking to target SLCs. Moreover, he presented recent work carried out in collaboration with an academic founding partner to identify chemical probes aimed at a promising target related to lactate metabolism.
The ReSOLUTE consortium is a public–private partnership supported by the IMI2 initiative with the aim of generating tools, reagents, and assays for the enabling of drug discovery on SLCs, a large but mostly understudied target class of membrane proteins.
A recording of the presentation, titled “Discovering the next SLC drug through a functional transport platform” is available on the conference website: RESOLUTE – Research Empowerment on Solute Carriers (re-solute.eu)
For more information, contact: office@solgate.com
Solgate GmbH pursues the development of drugs modulating the activity of SLC proteins, focusing on the important roles of SLCs in neurological, autoimmune, and metabolic disorders. Through a proprietary discovery platform that combines several technologies, Solgate designs and rapidly advances novel chemical matter against selected SLCs. Solgate GmbH was founded by Ariel Bensimon, Georg Winter, Stefan Kubicek, Giulio Superti-Furga, and Gaia Novarino, together with CeMM and IST Austria.